Abstract
Cross-linked hyaluronan gel (CHAG) is widely used as an anti-adhesion agent following surgery. This study demonstrates that CHAG also inhibits the migration, invasion, and proliferation of ovarian carcinoma (OC) cells in vitro and suppresses the development of implantation tumors in vivo. These findings suggest that CHAG serves a dual role as both an anti-tumor and anti-adhesion agent, offering a safer and more effective therapeutic option for OC patients.
Introduction
Ovarian cancer (OC) remains a significant clinical challenge due to its high metastatic potential and frequent recurrence. Metastasis often occurs through the exfoliation of cancer cells from the primary tumor, which then implant throughout the pelvic cavity. While surgery is a cornerstone of treatment, it frequently results in postoperative adhesions—internal scarring that impairs quality of life.
Anti-adhesive barriers, such as CHAG, are standard for preventing these complications. However, concerns existed regarding whether such gels might inadvertently facilitate cancer cell growth by providing a scaffold. This research investigates the safety and potential anti-cancer efficacy of CHAG in the context of ovarian carcinoma.
Methodology
The study employed a multi-faceted approach using human ovarian cancer cell lines (A2780 and SKOV3).
- In Vitro Assays: Transwell migration and invasion assays were used to quantify the movement of cells through membranes and extracellular matrices. Molecular signaling was analyzed via Western blotting to track the activation of the EGF/EGFR pathway and downstream effectors like Akt and ERK.
- In Vivo Models: Female nude BALB/c mice were used to simulate peritoneal metastasis. Mice were injected with OC cells, and the experimental group received CHAG to evaluate its impact on tumor implantation and growth.
Results and Discussion
Inhibition of Cellular Motility and Invasion
Experimental results revealed that CHAG acts as more than just a physical lubricant. At a concentration of 1000 μg/mL, CHAG significantly suppressed both baseline and EGF-induced migration and invasion in both A2780 and SKOV3 cell lines.
Suppression of Tumor Growth In Vivo
The anti-tumor effects observed in the laboratory translated effectively to animal models. In nude mice, CHAG treatment led to a significant reduction in the weight of transplanted tumors and a noticeable delay in tumor progression compared to untreated controls.
Mechanistic Insights
The study identified that CHAG effectively "masks" the cell surface, preventing Epidermal Growth Factor (EGF) from binding to its receptor (EGFR). This blockade shuts down the Akt and ERK signaling pathways, which are critical for cell division and survival. Furthermore, CHAG suppresses the activity of Rac1, a protein essential for the cytoskeletal changes required for cell movement, effectively paralyzing the cells' invasive capabilities.
Conclusion
CHAG represents a unique "double-threat" therapeutic agent. By simultaneously preventing post-surgical adhesions and actively inhibiting ovarian cancer metastasis and growth, it addresses two of the most critical issues in OC management. While further clinical trials are necessary to confirm these effects in human patients, these findings provide strong evidence for the safety and therapeutic potential of CHAG in oncological surgery.
Summary updated